Pharmacodynamic and pharmacokinetic properties of insulin glulisine (Apidra) in comparison to insulin lispro (Humalog) in healthy lean and obese subjects

Trial Profile

Pharmacodynamic and pharmacokinetic properties of insulin glulisine (Apidra) in comparison to insulin lispro (Humalog) in healthy lean and obese subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Insulin glulisine; Insulin lispro
  • Indications Diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Dec 2009 Actual initiation date (Apr 2004) and actual end date (Oct 2004) added as reported by ClinicalTrials.gov.
    • 12 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top